Table 5.
Simulated Transthyretin Levels Over Time for Various Dosing Regimens
| Dose | Day | TTR level (mg/dL) | TTR % change from baseline (%) |
|---|---|---|---|
| 300 mg QW | Baseline | 20.4 (19.7–21.2) | NA |
| Day 7 | 15.7 (15.0–16.4) | −20.2 (−23.0 to −17.5) | |
| Day 14 | 12.4 (11.8–13.1) | −34.8 (−37.9 to −32.0) | |
| Day 28 | 8.91 (8.33–9.53) | −51.2 (−54.1 to −48.4) | |
| Day 85 | 5.56 (5.12–6.02) | −67.9 (−70.2 to −65.5) | |
| Day (steady state) | 4.82 (4.41–5.22) | −71.9 (−74.0 to −69.7) | |
| 300 mg QW with loading dose | Baseline | 20.4 (19.7–21.1) | NA |
| Day 7 | 13.0 (12.4–13.7) | −32.5 (−35.3 to −29.2) | |
| Day 14 | 10.3 (9.72–11.0) | −45.1 (−47.8 to −42.3) | |
| Day 28 | 7.67 (7.10–8.26) | −57.5 (−60.4 to −54.8) | |
| Day 85 | 7.39 (6.84–7.96) | −69.0 (−71.1 to −66.8) | |
| Day (steady state) | 4.78 (4.39–5.22) | −71.9 (−74.1 to −69.8) | |
| 300 mg Q2W | Baseline | 20.4 (19.7–21.2) | NA |
| Day 7 | 15.7 (15.0–16.4) | −20.2 (−23.0 to −17.5) | |
| Day 14 | 14.6 (13.9–15.3) | −24.7 (−27.8 to −21.8) | |
| Day 28 | 11.7 (11.0–12.6) | −38.0 (−41.1 to −35.0) | |
| Day 85 | 8.29 (7.70–8.92) | −53.8 (−56.7 to −50.9) | |
| Day (steady state) | 7.24 (6.67–7.82) | −58.8 (−61.5 to −56.1) | |
| 150 mg QW | Baseline | 20.4 (19.7–21.2) | NA |
| Day 7 | 16.6 (15.9–17.4) | −15.9 (−18.6 to −13.3) | |
| Day 14 | 13.9 (13.3–14.6) | −28.1 (−31.5 to −25.3) | |
| Day 28 | 10.8 (10.1–11.4) | −42.6 (−45.6 to −39.6) | |
| Day 85 | 7.39 (6.84–7.96) | −58.6 (−61.2 to −56.0) | |
| Day (steady state) | 6.47 (5.95–6.98) | −63.1 (−65.7 to −60.5) |